THE WHAT? Waldencast reported its Q4 2025 and full-year 2025 financial results, with revenue broadly flat year-on-year as the company continued investing in brand growth and medical aesthetics expansion.
THE DETAILS The beauty and wellness platform reported FY 2025 net revenue of US$272.1 million, broadly unchanged from 2024, with adjusted EBITDA of US$16.1 million. Fourth-quarter revenue totaled US$72.0 million, also flat year-on-year, with adjusted EBITDA of US$6.6 million.
Within the portfolio, Obagi Medical delivered strong momentum, benefiting from international demand and U.S. direct-to-consumer growth, supported by investments tied to the launch of its injectable aesthetics platform. Meanwhile, Milk Makeup expanded U.S. distribution, including launches at Ulta Beauty and Amazon Premium Beauty, although softer international demand weighed on overall revenue.
During the year, Waldencast also strengthened its financial position through the sale of the Obagi Japan trademark to Rohto Pharmaceutical for US$82.5 million and refinancing its credit facility. The company said it is conducting a strategic review to explore options to maximise shareholder value.
THE WHY? The results reflect Waldencast’s strategy to transform its portfolio, expand into medical aesthetics, strengthen its financial structure and position its brands for long-term growth.
Source: Globnewswire
